Morphic Therapeutic stock nosedives on disappointing trial data

With two Big Pharmas abandoning partnerships and its only clinical-stage drug posting less-than-encouraging data, Waltham's Morphic Therapeutic has had a rough couple of years.

Orlando’s Church Street Station may get restaurants, bar, glass water tower

Brown Brothers Harriman launches women’s networking group

A sign of ‘modern society’: More multiracial families in commercials

Corner Lot project with workforce housing component gets approval

Shaq is bringing his Big Chicken franchise to Tampa Bay

Development of micro-apartments eyed for large swaths of Bellevue

Two Regions Financial Corp. directors to retire

Multifamily investment team jumps to Cushman & Wakefield’s Houston office

Morphic Therapeutic stock nosedives on disappointing trial data

Previous Judge rejects, rewrites summary for Missouri abortion initiative petition

Next Regions Bank inks first jersey sponsorship deal with Nashville Predators

firststargroup

Kotek touts $500M Oregon housing plan at Leadership Summit

Retirement plans see boost as states mandate IRAs and tax credits lower costs

Norton Healthcare data breach affected more than 2 million people

Houston-based cell therapy company FibroBiologics files to go public

Suggested Posts

Sana Yoga stretches with rebrand and expansion plans

A glimpse at the 14 KC ballpark sites the Royals have scouted

2022 Executives of the Year: Alex Melugin, Phoenix Home Care & Hospice

Top health leaders headline 10th annual gathering of Health Connect South

Three Strands Recovery Wear launches pilot test of Resilience Bra with Atrium, Novant surgeons

This Old Louisville home has a pool in its basement (PHOTOS)

MENU

FirstStar Group

More Stories

Opinion: The end of an era

Previous Judge rejects, rewrites summary for Missouri abortion initiative petition

Next Regions Bank inks first jersey sponsorship deal with Nashville Predators

firststargroup

Related Posts

Suggested Posts

MENU

FirstStar Group

More Stories